Cargando…
Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy
Background. Chemoimmunotherapy has become the first-line treatment for unresectable esophageal squamous cell carcinoma (ESCC). Still, reliable biomarkers to identify patients who could benefit from this combined therapy remain uncertain. This study focused on elucidating the predictive significance...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689525/ https://www.ncbi.nlm.nih.gov/pubmed/36421355 http://dx.doi.org/10.3390/curroncol29110702 |
_version_ | 1784836556922552320 |
---|---|
author | Ma, Xiaolu Ding, Yongfeng Qian, Jiong Wan, Mingyu Li, Ning Mao, Chenyu Xiao, Cheng Jiang, Haiping Zheng, Yulong Wu, Luntao Chen, Xiaoyu Xu, Nong |
author_facet | Ma, Xiaolu Ding, Yongfeng Qian, Jiong Wan, Mingyu Li, Ning Mao, Chenyu Xiao, Cheng Jiang, Haiping Zheng, Yulong Wu, Luntao Chen, Xiaoyu Xu, Nong |
author_sort | Ma, Xiaolu |
collection | PubMed |
description | Background. Chemoimmunotherapy has become the first-line treatment for unresectable esophageal squamous cell carcinoma (ESCC). Still, reliable biomarkers to identify patients who could benefit from this combined therapy remain uncertain. This study focused on elucidating the predictive significance of the monocyte-to-lymphocyte ratio (MLR) and establishing the prognostic nomogram for unresectable ESCC treated with chemoimmunotherapy. Methods. Data of clinical features, peripheral blood parameters, and treatment records were collected in unresectable ESCC patients who received PD-1/PD-L1 inhibitors plus chemotherapy as the first-line treatment from September 2017 to August 2021. The nomogram based on MLR and clinical parameters for predicting the overall survival (OS) was developed and validated. Results. Out of 81 patients enrolled, patients with a lower MLR had significantly longer progression-free survival (PFS) and OS than patients with a higher pretreatment MLR (p = 0.0067; p = 0.00069). The OS nomogram integrating MLR, performance status (PS) score, and body mass index (BMI) achieved a C-index of 0.770 (95%CI 0.645–0.896). The area under the ROC curve (AUC) value of the nomogram predicting 12-, 18-, and 24-month OS rates were 0.855, 0.792, and 0.744, respectively, which were higher than the clinical TNM staging system or the MLR. Stratified by the nomogram-generated scores, three risk groups (low, moderate, and high) in survival curves manifested a distinct difference (p < 0.0001). Conclusion. MLR emerged as an independent predictive factor for PFS and OS in treatment-naive unresectable ESCC patients treated with chemoimmunotherapy. The constructed nomogram of MLR and clinical parameters was a reliable model for prognostic estimation. |
format | Online Article Text |
id | pubmed-9689525 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96895252022-11-25 Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy Ma, Xiaolu Ding, Yongfeng Qian, Jiong Wan, Mingyu Li, Ning Mao, Chenyu Xiao, Cheng Jiang, Haiping Zheng, Yulong Wu, Luntao Chen, Xiaoyu Xu, Nong Curr Oncol Article Background. Chemoimmunotherapy has become the first-line treatment for unresectable esophageal squamous cell carcinoma (ESCC). Still, reliable biomarkers to identify patients who could benefit from this combined therapy remain uncertain. This study focused on elucidating the predictive significance of the monocyte-to-lymphocyte ratio (MLR) and establishing the prognostic nomogram for unresectable ESCC treated with chemoimmunotherapy. Methods. Data of clinical features, peripheral blood parameters, and treatment records were collected in unresectable ESCC patients who received PD-1/PD-L1 inhibitors plus chemotherapy as the first-line treatment from September 2017 to August 2021. The nomogram based on MLR and clinical parameters for predicting the overall survival (OS) was developed and validated. Results. Out of 81 patients enrolled, patients with a lower MLR had significantly longer progression-free survival (PFS) and OS than patients with a higher pretreatment MLR (p = 0.0067; p = 0.00069). The OS nomogram integrating MLR, performance status (PS) score, and body mass index (BMI) achieved a C-index of 0.770 (95%CI 0.645–0.896). The area under the ROC curve (AUC) value of the nomogram predicting 12-, 18-, and 24-month OS rates were 0.855, 0.792, and 0.744, respectively, which were higher than the clinical TNM staging system or the MLR. Stratified by the nomogram-generated scores, three risk groups (low, moderate, and high) in survival curves manifested a distinct difference (p < 0.0001). Conclusion. MLR emerged as an independent predictive factor for PFS and OS in treatment-naive unresectable ESCC patients treated with chemoimmunotherapy. The constructed nomogram of MLR and clinical parameters was a reliable model for prognostic estimation. MDPI 2022-11-18 /pmc/articles/PMC9689525/ /pubmed/36421355 http://dx.doi.org/10.3390/curroncol29110702 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ma, Xiaolu Ding, Yongfeng Qian, Jiong Wan, Mingyu Li, Ning Mao, Chenyu Xiao, Cheng Jiang, Haiping Zheng, Yulong Wu, Luntao Chen, Xiaoyu Xu, Nong Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy |
title | Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy |
title_full | Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy |
title_fullStr | Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy |
title_full_unstemmed | Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy |
title_short | Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy |
title_sort | nomogram based on monocyte-to-lymphocyte ratio to predict survival of unresectable esophageal squamous cell carcinoma who receive first-line pd-1/pd-l1 inhibitors combined with chemotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689525/ https://www.ncbi.nlm.nih.gov/pubmed/36421355 http://dx.doi.org/10.3390/curroncol29110702 |
work_keys_str_mv | AT maxiaolu nomogrambasedonmonocytetolymphocyteratiotopredictsurvivalofunresectableesophagealsquamouscellcarcinomawhoreceivefirstlinepd1pdl1inhibitorscombinedwithchemotherapy AT dingyongfeng nomogrambasedonmonocytetolymphocyteratiotopredictsurvivalofunresectableesophagealsquamouscellcarcinomawhoreceivefirstlinepd1pdl1inhibitorscombinedwithchemotherapy AT qianjiong nomogrambasedonmonocytetolymphocyteratiotopredictsurvivalofunresectableesophagealsquamouscellcarcinomawhoreceivefirstlinepd1pdl1inhibitorscombinedwithchemotherapy AT wanmingyu nomogrambasedonmonocytetolymphocyteratiotopredictsurvivalofunresectableesophagealsquamouscellcarcinomawhoreceivefirstlinepd1pdl1inhibitorscombinedwithchemotherapy AT lining nomogrambasedonmonocytetolymphocyteratiotopredictsurvivalofunresectableesophagealsquamouscellcarcinomawhoreceivefirstlinepd1pdl1inhibitorscombinedwithchemotherapy AT maochenyu nomogrambasedonmonocytetolymphocyteratiotopredictsurvivalofunresectableesophagealsquamouscellcarcinomawhoreceivefirstlinepd1pdl1inhibitorscombinedwithchemotherapy AT xiaocheng nomogrambasedonmonocytetolymphocyteratiotopredictsurvivalofunresectableesophagealsquamouscellcarcinomawhoreceivefirstlinepd1pdl1inhibitorscombinedwithchemotherapy AT jianghaiping nomogrambasedonmonocytetolymphocyteratiotopredictsurvivalofunresectableesophagealsquamouscellcarcinomawhoreceivefirstlinepd1pdl1inhibitorscombinedwithchemotherapy AT zhengyulong nomogrambasedonmonocytetolymphocyteratiotopredictsurvivalofunresectableesophagealsquamouscellcarcinomawhoreceivefirstlinepd1pdl1inhibitorscombinedwithchemotherapy AT wuluntao nomogrambasedonmonocytetolymphocyteratiotopredictsurvivalofunresectableesophagealsquamouscellcarcinomawhoreceivefirstlinepd1pdl1inhibitorscombinedwithchemotherapy AT chenxiaoyu nomogrambasedonmonocytetolymphocyteratiotopredictsurvivalofunresectableesophagealsquamouscellcarcinomawhoreceivefirstlinepd1pdl1inhibitorscombinedwithchemotherapy AT xunong nomogrambasedonmonocytetolymphocyteratiotopredictsurvivalofunresectableesophagealsquamouscellcarcinomawhoreceivefirstlinepd1pdl1inhibitorscombinedwithchemotherapy |